TLX
Telix Pharmaceuticals Limited
NASDAQ · Healthcare · Biotechnology · AU
$11.94
+1.70%Year over year
Reported trailing growth
- Revenue
- +202.0%
- EBITDA
- +364.0%
- EBIT
- +272.5%
- EPS
- +597.6%
- Free cash flow
- —
- Operating cash flow
- -78.7%
Forward estimates
Based on analyst estimates
- Revenue
- -72.2%
- EBITDA
- +72.8%
- EPS
- -25.1%
Three-year CAGR
- Revenue
- +96.0%
- EBITDA
- +86.4%
- EBIT
- +29.7%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026